leadf
logo-loader
viewAnteris Technologies Ltd

Admedus Limited non-executive director exercises options

au_admedus_manufacturing_facility_3_358_5514b04089113.jpg

Admedus Limited (ASX:AHZ) non-executive director Peter Turvey has increased his stake in the company through the exercise of 333,333 unlisted options exercisable at $0.06 each.

AHZ last traded at $0.074.

Turvey paid $19,999.98 to convert the options into 333,333 shares, increasing his direct and indirect interest up to 2,775,535 shares.

He retains 333,334 of the same unlisted options exercisable at $0.06 and expiring 18 May 2017 as well as 500,000 unlisted options exercisable at $0.27 that expire on 16 December 2018.

Admedus recently raised $12 million through a heavily oversubscribed placement to boost sales and advance its regenerative tissue product development and immunotherapy programs.

It will also undertake a 1 for 7 non-renounceable pro-rata offer of shares priced at $0.07 to raise up to $16 million.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Anteris Technologies Ltd

Price: 3.92 AUD

ASX:AVR
Market: ASX
Market Cap: $23.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read